Eva Fortea Verdejo
Stock Analyst at Wells Fargo
(4.93)
# 168
Out of 4,703 analysts
104
Total ratings
84.4%
Success rate
56.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eva Fortea Verdejo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Rated: Buy | $240 | $210.02 | +14.27% | 12 | Aug 27, 2026 | |
| ZYME Zymeworks | Rated: Buy | $40 | $29.19 | +37.03% | 9 | Aug 25, 2026 | |
| CELC Celcuity | Maintained: Buy | $166 | $95.70 | +73.46% | 7 | Aug 14, 2026 | |
| STRO Sutro Biopharma | Rated: Buy | $27 → $49 | $20.07 | +144.15% | 3 | Aug 13, 2026 | |
| BCAX Bicara Therapeutics | Rated: Hold | $16 → $23 | $23.17 | -0.73% | 11 | Aug 12, 2026 | |
| EXEL Exelixis | Rated: Hold | $49 → $50 | $59.01 | -15.27% | 5 | Aug 6, 2026 | |
| RCUS Arcus Biosciences | Rated: Hold | $23 → $26 | $29.66 | -12.34% | 9 | Aug 6, 2026 | |
| IDYA IDEAYA Biosciences | Maintained: Buy | $48 | $39.86 | +20.42% | 6 | Aug 5, 2026 | |
| KNSA Kiniksa Pharmaceuticals International, | Rated: Buy | $74 → $87 | $77.91 | +11.67% | 16 | Jul 29, 2026 | |
| GMAB Genmab | Rated: Buy | $40 | $33.60 | +19.05% | 7 | Jun 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $21 | $19.04 | +10.29% | 9 | May 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $5 | $3.99 | +25.31% | 1 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $60 | $36.13 | +66.07% | 3 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $27 | $26.61 | +1.47% | 6 | Oct 23, 2025 |
Revolution Medicines
Aug 27, 2026
Rated: Buy
Price Target: $240
Current: $210.02
Upside: +14.27%
Zymeworks
Aug 25, 2026
Rated: Buy
Price Target: $40
Current: $29.19
Upside: +37.03%
Celcuity
Aug 14, 2026
Maintained: Buy
Price Target: $166
Current: $95.70
Upside: +73.46%
Sutro Biopharma
Aug 13, 2026
Rated: Buy
Price Target: $27 → $49
Current: $20.07
Upside: +144.15%
Bicara Therapeutics
Aug 12, 2026
Rated: Hold
Price Target: $16 → $23
Current: $23.17
Upside: -0.73%
Exelixis
Aug 6, 2026
Rated: Hold
Price Target: $49 → $50
Current: $59.01
Upside: -15.27%
Arcus Biosciences
Aug 6, 2026
Rated: Hold
Price Target: $23 → $26
Current: $29.66
Upside: -12.34%
IDEAYA Biosciences
Aug 5, 2026
Maintained: Buy
Price Target: $48
Current: $39.86
Upside: +20.42%
Kiniksa Pharmaceuticals International,
Jul 29, 2026
Rated: Buy
Price Target: $74 → $87
Current: $77.91
Upside: +11.67%
Genmab
Jun 29, 2026
Rated: Buy
Price Target: $40
Current: $33.60
Upside: +19.05%
May 19, 2026
Maintained: Buy
Price Target: $21
Current: $19.04
Upside: +10.29%
May 13, 2026
Rated: Hold
Price Target: $5
Current: $3.99
Upside: +25.31%
Apr 14, 2026
Maintained: Buy
Price Target: $60
Current: $36.13
Upside: +66.07%
Oct 23, 2025
Maintained: Buy
Price Target: $27
Current: $26.61
Upside: +1.47%